AR046886A1 - Analogos de rifamicina y usos de los mismos. - Google Patents

Analogos de rifamicina y usos de los mismos.

Info

Publication number
AR046886A1
AR046886A1 ARP040104623A ARP040104623A AR046886A1 AR 046886 A1 AR046886 A1 AR 046886A1 AR P040104623 A ARP040104623 A AR P040104623A AR P040104623 A ARP040104623 A AR P040104623A AR 046886 A1 AR046886 A1 AR 046886A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkaryl
heteroaryl
aryl
alkylheteroaryl
Prior art date
Application number
ARP040104623A
Other languages
English (en)
Original Assignee
Activbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activbiotics Inc filed Critical Activbiotics Inc
Publication of AR046886A1 publication Critical patent/AR046886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente se refiere a composición farmacéutica que los contiene y usos. Reivindicación 1: Un compuesto que tiene la fórmula (1), o una de sus sales farmacéuticamente aceptables, en donde: a) A es H, OH, O-(alquilo C1-6), O-(alcarilo C1-4), O- (arilo C6-12), O-(heteroarilo C1-9), u O-(alqheteroarilo C1-4); W es O, S o NR1, en donde R1 es H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4; X es H o COR2, en donde R2 es alquilo C1-6, que puede estar sustituido con 1-5 grupos OH, O- (alquilo C3-7), que puede estar sustituido con 1-4 grupos OH, arilo C6-12, alcarilo C1-4, heteroarilo C1-9, o alqheteroarilo C1-4, en donde cada carbono del alquilo está unido a no más de un átomo de oxígeno; Y es H, Hal, u OR3, en donde R3 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4; R4 es OR5, SR5 o NR5R6, en donde R5 se define más abajo en relación con R7 y R6 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4, COR9, CO2R9, CONHR9, CSR9, COSR9, CSOR9, CSNHR9, SO2R9 o SO2NHR9, en donde R9 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo o alqheteroarilo C1-4; y Z es (CR11R12)nNR7R8, en donde n es 0 ó 1, R7 y R5 representan juntos un enlace o forman un enlace C1-4 sustituido o insustituido, R8 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4, COR10, CO2R10, CONHR10, CSR10, COSR10, CSOR10, CSNHR10, SO2R10 o SO2NHR10, en donde R10 es alquilo C1-6, arilo C6- 12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4 o R8 no existe y se forma un enlace doble entre N y un enlace de carbono C1 R5-R7, cada uno de R11 y R12 es, de modo independiente, H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4 o R12 no existe y se forma un enlace doble entre N y el carbono que lleva R11; o b) A es H, OH, O-(alquilo C1-6), O-(alcarilo C1-4), O-(arilo C6-12), O-(heteroarilo C1-9), u O-(alqheteroarilo C1-4); W es O, S o NR1, en donde R1 es H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4; X es H o COR2, en donde R2 es alquilo C1-6, que puede estar sustituido con 1-5 grupos OH, O-(alquilo C3-7), que puede estar sustituido con 1-4 grupos OH, arilo C6-12, alcarilo C1-4, heteroarilo C1-9, o alqheteroarilo C1-4, en donde cada carbono del alquilo está unido a no más de un átomo de oxígeno; Z es H, Hal, u OR3, en donde R3 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4; R4 es OR5, SR5 o NR5R6, en donde R5 se define más abajo en relación con R7 y R6 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4, COR9, CO2R9, CONHR9, CSR9, COSR9, CSOR9, CSNHR9, SO2R9 o SO2NHR9, en donde R9 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo o alqheteroarilo C1-4; y Y es (CR11R12)nNR7R8, en donde n es 0 ó 1, R7 y R5 representan juntos un enlace o forman un enlace C1-4 sustituido o insustituido, R8 es H, alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1- 9 o alqheteroarilo C1-4, COR10, CO2R10, CONHR10, CSR10, COSR10, CSOR10, CSNHR10, SO2R10 o SO2NHR10, en donde R10 es alquilo C1-6, arilo C6-12, alcarilo C1-4, heteroarilo C1-9 o alqheteroarilo C1-4 o R8 no existe y se forma un enlace doble entre N y un enlace de carbono C1 R5-R7, cada uno de R11 y R12 es, de modo independiente, H, alquilo C1-6, alcarilo C1-4 o alqheteroarilo C1-4 o R12 no existe y se forma un enlace doble entre N y el carbono que lleva R11.
ARP040104623A 2003-12-10 2004-12-10 Analogos de rifamicina y usos de los mismos. AR046886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52873303P 2003-12-10 2003-12-10

Publications (1)

Publication Number Publication Date
AR046886A1 true AR046886A1 (es) 2005-12-28

Family

ID=34699896

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104623A AR046886A1 (es) 2003-12-10 2004-12-10 Analogos de rifamicina y usos de los mismos.

Country Status (9)

Country Link
US (2) US7220738B2 (es)
EP (1) EP1697382A4 (es)
JP (1) JP2007513961A (es)
KR (1) KR20070015506A (es)
AR (1) AR046886A1 (es)
AU (1) AU2004298983A1 (es)
CA (1) CA2549001A1 (es)
TW (1) TW200529856A (es)
WO (1) WO2005058231A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
AU2004268531A1 (en) * 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
KR20070006698A (ko) 2003-12-23 2007-01-11 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007070613A2 (en) * 2005-12-14 2007-06-21 Activbiotics, Incorporated Rifamycin analogs and uses thereof
CN101432044A (zh) * 2006-04-28 2009-05-13 恩迪尼国际有限公司 光消毒装置和方法
WO2009064792A1 (en) * 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Quinolone carboxylic acid-substituted rifamycin derivatives
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8586029B2 (en) * 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
EP2330901A4 (en) * 2008-09-17 2012-03-07 Sphingomonas Res Partners L P TREATMENT FOR LEUKEMIA AND IDIOPATHIC APLASTIC ANEMIA
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
CA2858372A1 (en) * 2011-11-10 2013-05-16 Lankenau Institute For Medical Research Compositions and methods for the prevention of microbial infections
AU2016304585B2 (en) 2015-08-05 2023-04-06 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College LIPIDED PSA COMPOSITIONS AND METHOD
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (es) * 1963-10-11
JPS58225093A (ja) 1982-06-25 1983-12-27 Kanegafuchi Chem Ind Co Ltd ベンゾチアジノリフアマイシン誘導体およびその製造法
JPS59231092A (ja) 1983-06-11 1984-12-25 Kanebo Ltd フエノチアジン型リフアマイシンおよびその医薬用途
US4690919A (en) * 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS6122090A (ja) 1984-07-09 1986-01-30 Kanebo Ltd アミノ置換フエノチアジン型リフアマイシンおよびその医薬用途
JPS62240688A (ja) 1986-04-12 1987-10-21 Kanegafuchi Chem Ind Co Ltd ヒドロキシメチル基を有するアミノベンゾキサジノおよびアミノベンゾチアジノリフアマイシン誘導体
JPS62242687A (ja) 1986-04-15 1987-10-23 Kanegafuchi Chem Ind Co Ltd 置換ベンゾキサジノおよび置換ベンゾチアジノリフアマイシン誘導体
JP2544375B2 (ja) * 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
JPS6335579A (ja) 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd 含硫ベンゾキサジノリフアマイシン誘導体
JPS6335578A (ja) * 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノまたはベンゾチアジノリフアマイシン誘導体
JPS63233987A (ja) 1987-03-23 1988-09-29 Kanegafuchi Chem Ind Co Ltd ４′−ｔｅｒｔ−ブチルベンゾキサジノリフアマイシン誘導体
DE68924722T2 (de) * 1988-03-18 1996-04-18 Kanegafuchi Chemical Ind Substituiertes Benzoxazinorifamycinderivat, Verfahren zur Herstellung und dieses Derivat enthaltende Bakterizidmittel.
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
WO1994008709A1 (en) * 1992-10-09 1994-04-28 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Production method for fine granulate
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
WO1997009047A1 (fr) 1995-09-01 1997-03-13 Kaneka Corporation Medicament contre des maladies causees par une infection par helicobacter
JP3963976B2 (ja) * 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
JPH10258509A (ja) * 1997-03-19 1998-09-29 Fujitsu Ltd インクジェットヘッド及びその製造方法
US6486161B1 (en) * 1998-07-29 2002-11-26 Kaneka Corporation Use of rifamycin derivative for treating mastitis in a domestic animal
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
AU2002368203A1 (en) * 2001-09-06 2004-05-04 Activbiotics, Inc. Antimicrobial agents and uses thereof
WO2003045319A2 (en) * 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
WO2003051299A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040014750A1 (en) * 2001-12-13 2004-01-22 Michaelis Arthur F. Metal complexes and formulations of rifamycin analogues and uses thereof
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
WO2003099217A2 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
WO2003101445A1 (en) * 2002-06-03 2003-12-11 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
AU2003268330A1 (en) * 2002-08-29 2004-03-19 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
AU2004268531A1 (en) * 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
KR20070006698A (ko) 2003-12-23 2007-01-11 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도

Also Published As

Publication number Publication date
US7494991B2 (en) 2009-02-24
KR20070015506A (ko) 2007-02-05
AU2004298983A1 (en) 2005-06-30
US20050137189A1 (en) 2005-06-23
US7220738B2 (en) 2007-05-22
CA2549001A1 (en) 2005-06-30
EP1697382A4 (en) 2008-11-05
US20070238747A1 (en) 2007-10-11
WO2005058231A2 (en) 2005-06-30
TW200529856A (en) 2005-09-16
JP2007513961A (ja) 2007-05-31
WO2005058231A3 (en) 2005-12-22
EP1697382A2 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
AR046886A1 (es) Analogos de rifamicina y usos de los mismos.
HUP0302825A2 (hu) Lipidben gazdag plakkok csökkentésére szolgáló szerek
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
HUP9901590A2 (hu) Szubsztituált aza- és diaza-cikloheptán- és -ciklooktán-származékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
AR049543A1 (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica
AR061181A1 (es) Compuestos de aziridinil-epotilona
ES2667477T3 (es) Compuestos heterobiciclo-sustituidos-[1,2,4]triazolo[1,5-c]quinazolin-5-amina adecuados para el tratamiento o la prevención de trastornos del sistema nervioso central
CO5690596A2 (es) Derivados de hexahidropirazino [1,2-a]pirimidin-4,7-diona sustituidos, en el nitrogeno, metodo para su produccion y su uso como medicamentos
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
HUP0402107A2 (hu) N-helyettesített pirrolidinszármazékok, mint dipeptidil-peptidáz IV inhibítorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
HK1084024A1 (en) Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
AR049372A1 (es) Compuestos biciclicos de amina y composiciones farmaceuticas que los comprenden
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
AR072301A1 (es) Derivados de acido fenoxicroman carboxilico 6-sustituido utiles en el tratamiento y/o prevencion de enfermedades alergicas e inflamatorias, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos y compuestos intermediarios.
GT200700084A (es) Derivados de indanil-piperazinas, su procedimiento de preparación y las composiciones farmaceuticas que los contienen.
AR068056A1 (es) Derivados de n, n'-2, 4 - dianilinopirimidinas, su preparacion, su uso como medicamentos, composiciones farmaceuticas y especialmente como inhibidores de ikk.
AR080802A1 (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro
AR070733A1 (es) Derivados de platino-carbeno n-heterociclico, su preparacion, su composicion farmaceutica y su uso para el tratamiento del cancer
CO5031250A1 (es) Compuesto farmaceutico
AR061377A1 (es) Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares.
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR070910A1 (es) Derivados de sulfonamida sustituida

Legal Events

Date Code Title Description
FB Suspension of granting procedure